MAPK8 and cancer: Although there is limited peer-reviewed biochemical data available for CC-401, recent in vivo studies have demonstrated that this well-tolerated compound can sensitize colon cancers to various treatments [24], and inhibit metastatic triple negative breast cancers (TNBCs) by blocking JNK-dependent primary tumor growth, cancer stemness, invasion and metastatic niche development [12,13].